Showing 2251-2260 of 5771 results for "".
- EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-yutiq-presentations-at-aao-annual-meeting/2476921/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Aca
- Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-allergic-conjunctivitis/2476914/Ocular Therapeutix announced that it has dosed the first patients in its phase 3 clinical trial of Dextenza for the treatment of symptoms of allergic conjunctivitis. Allergic conjunctivitis refers to inflammation of the conjunctiva of the eye caused by an allergic reaction–generally from airborne
- Haag-Streit Announces the Launch of the Ellex Eye Prime in UKhttps://modernod.com/news/haag-streit-uk-announces-the-launch-of-the-ellex-eye-prime/2476912/Haag-Streit UK (HS-UK) has announced the launch of the Eye Prime diagnostic ultrasound system in the UK. The Eye Prime is the next-generation ultrasound solution from Ellex. It features the industry’s first and only “six-ring phased annular array technology,” delivering crisp, high-de
- Vertical Pharmaceuticals Announces Submission of New Drug Application for RVL-1201https://modernod.com/news/vertical-pharmaceuticals-announces-submission-of-new-drug-application-for-rvl-1201/2476894/Vertical Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced the submission of a new drug application (NDA) to the FDA for approval of RVL-1201 (RVL) for the treatment of acquired blepharoptosis (droopy eyelid). RVL is a novel, once-daily ophthalmic formulation of oxymeta
- Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Boardhttps://modernod.com/news/oculis-announces-appointment-of-leading-ophthalmology-specialists-to-scientific-advisory-board/2476888/Oculis SA announced the appointments of Eric Donnenfeld, MD, and Pr. Ramin Tadayoni, MD, PhD, to its Scientific Advisory Board (SAB). “I am pleased to welcome Eric and Ramin to our SAB and look forward to their contributions as we focus on our objective of developing topical medicines that
- PECAA and Medical Eyeglass Center Announce Partnershiphttps://modernod.com/news/pecaa-and-medical-eyeglass-center-announce-partnership/2476885/PECAA, a nationwide Doctor Alliance Group currently serving over 3,700 independent eye care practitioners, announced that it has entered into a strategic partnership with Medical Eyeglass Center (MEC), an optical disp
- Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meetinghttps://modernod.com/news/kodiak-sciences-announces-emerging-durability-data-from-ongoing-phase-1b-study-of-ksi-301-in-wet-amd-patients-at-the-retina-society-annual-meeting/2476886/Kodiak Sciences announced emerging durability data in patients with wet age-related macular degeneration (AMD) treated in its phase 1b clinical study of its investigational therapy KSI-301. The results were presented by David M. Brown</
- Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing Iluvien in Benelux Countrieshttps://modernod.com/news/alimera-announces-expansion-of-agreement-with-distribution-partner-horus-pharma-to-include-marketing-iluvien-in-benelux-countries/2476878/Alimera Sciences announced that it has expanded its relationship with Horus Pharma, one of the company’s current distributors of Iluvien in Europe. Following the successful launch of Iluvien for diabetic macular edema (DME) in France by Horus Pharma, Alimera Sciences and Horus have agreed to expa
- Registration Now Open for International Sports Vision Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-annual-conference/2476869/Registration is now open for Beyond 20/20, the 4th annual International Sports Vision Association (ISVA) conference, February 6-8, 2020, at the Bahia Resort Hotel in San Diego, California. “Sports Vision, the science of helping athletes reach peak levels of performance through t
- Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercepthttps://modernod.com/news/novartis-announces-details-of-talon-global-clinical-trial-in-wet-amd-comparing-brolucizumab-vs-aflibercept/2476870/In the phase 3b TALON clinical trial, Novartis announced that the two primary endpoints are superiority for brolucizumab in treatment interval duration and noninferiority in change in visual acuity. Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resol